


## JTP-4819

Cat. No.:	HY-15112
CAS No.:	162203-65-8
Molecular Formula:	C <sub>19</sub> H <sub>25</sub> N <sub>3</sub> O <sub>4</sub>
Molecular Weight:	359.42
Target:	Prolyl Endopeptidase (PREP)
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	JTP-4819 is a potent and specific inhibitor of prolyl endopeptidase (PREP) with IC <sub>50</sub> s of 0.83 nM (in rat brain supernatant) and 5.43 nM (in <i>Flavobacterium meningosepticum</i> ). JTP-4819 has blood-brain penetration, also improves the retention time of amnesia rats induced by <a href="#">Scopolamine</a> (HY-N2096) <sup>[1][2]</sup> .																																	
<b>In Vitro</b>	JTP-4819 inhibits the degradation of substance P, arginine-vasopressin, thyrotropin-releasing hormone, neurotensin, oxytocin, bradykinin, and angiotensin II by purified PREP with IC <sub>50</sub> s of 9.6, 13.9, 10.7, 14.0, 4.5, 7.6 and 10.6 nM, respectively [1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.																																	
<b>In Vivo</b>	<p>JTP-4819 (1 and 3 mg/kg 1 hr before acquisition or at 3 and 10 mg/kg 1 hr before; p.o.) significantly prolonged the retention time in the one-trial passive avoidance test in rats with <a href="#">Scopolamine</a> (HY-N2096)-induced amnesia<sup>[1]</sup>.</p> <p>JTP-4819 (1 mg/kg and 3 mg/kg; p.o.; single dose) causes a significant increase in ACh release in the frontal cortex and hippocampus of young rats, as well as in both brain regions of aged rats at higher dose<sup>[1]</sup>.</p> <p>JTP-4819 combined with substance P, arginine-vasopressin or thyrotropin-releasing hormone, improves the retention time of rats with scopolamine-induced amnesia<sup>[1]</sup>.</p> <p>Brain pharmacokinetics in rats<sup>[2]</sup></p> <table border="1"> <thead> <tr> <th></th> <th>AUC<sub>0-300 min</sub> (μg·min)</th> <th>C<sub>max</sub> (μM)</th> <th>Brain/blood ratio</th> <th>t<sub>1/2β</sub> (min)</th> </tr> </thead> <tbody> <tr> <td>Unbound concentrations</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Blood</td> <td>1947</td> <td>16.7</td> <td></td> <td>84</td> </tr> <tr> <td>Cortex</td> <td>206</td> <td>1.78</td> <td>0.13</td> <td>77</td> </tr> <tr> <td>Hippocampus</td> <td>128</td> <td>1.05</td> <td>0.09</td> <td>105</td> </tr> <tr> <td>Striatum</td> <td>178</td> <td>1.26</td> <td>0.10</td> <td>128</td> </tr> </tbody> </table>					AUC <sub>0-300 min</sub> (μg·min)	C <sub>max</sub> (μM)	Brain/blood ratio	t <sub>1/2β</sub> (min)	Unbound concentrations					Blood	1947	16.7		84	Cortex	206	1.78	0.13	77	Hippocampus	128	1.05	0.09	105	Striatum	178	1.26	0.10	128
	AUC <sub>0-300 min</sub> (μg·min)	C <sub>max</sub> (μM)	Brain/blood ratio	t <sub>1/2β</sub> (min)																														
Unbound concentrations																																		
Blood	1947	16.7		84																														
Cortex	206	1.78	0.13	77																														
Hippocampus	128	1.05	0.09	105																														
Striatum	178	1.26	0.10	128																														

---

Total tissue  
concentrations

Plasma	4230	78.6		130
Brain	145	1.47	0.034	120

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

[1]. Toide K, et al. JTP-4819: a novel prolyl endopeptidase inhibitor with potential as a cognitive enhancer. J Pharmacol Exp Ther. 1995 Sep;274(3):1370-8.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA